

A philosophical and scientific approach to evaluate preventive & curative medicinal uses of herbal, natural products, food additives, nutraceuticals (ayurveda) and pharmaceuticals (allopath)

D L Sharma

Omatek lab Pvt Ltd, India

It is very important to evaluate classical and recent development of medicinal systems, their basic principal and truth behind their usage, this is an approach to take insight view on Pharmaceuticals and a most ancient systems of medicines in the world. Ayurvedic medicines are one of the most ancient systems of treatment in India & now spreading globally. India has a rich heritage of usage of Ayurvedic & Herbal medicines supported by nutraceuticals. Ayurveda and Herbal have just recently started rising on the horizon of alternative system of medicine. Ayurveda and Herbal were being practiced, used and now getting legal support all over the world. Current Global market of Herbal & Ayurvedic medicines is estimated to be more than US\$ 100 billion, out of this E.U. accounts for about 40%, Japan 20%, USA 10%. The Asian countries together account for 30% of the global market Its uses are more as food additives, preventive medicines and now curative specifically diseases related to elementary canal. Unani system is also similar to Ayurveda with some exeptions Allopath (Pharmaceuticals) and modern surgery supported by scientific evaluation, chemistry and clinical study has vast area of use for quick relief, globally 70% people use this system in case of cure disease. Homeopathy is a medicinal system their basic principal is based on natural body reaction, it is more body science then chemistry is best system for allergy.

Biography

D L Sharma has completed his Ph.D in 2001, at the age of 45 years from Maulana Azad College of Technology (MACT) Bhopal MP. He was in Athletics and created record for MP, Indore & Ujjain university Athletics, also he was captain of these teams, Taken many training in R&D Instrumentation and QA/QC Systems in India and abroad, visited Singapore, Viena (Austria), Hongkong, China and USA. He has setup QA Systems and QC Lab in Lupin, orchid and zydus cadila, now set up his own lab and business, now he is the Managing director of Omatek lab Pvt ltd Indore India, a R&D Based pharma nutra mfg co since last 8 yrs, Prior to this co he was in Lupin R&D for 7 yrs, in Orchid Chemicals QA/QC for 9 yrs and Zydus cadila / other pharma companies for 8 yr total 32 yr experience in pharma / nutra industry. He has set up four reputed QC/R&D lab and worked as team leaders of up to 50 scientists, Presented hes speech / lectures in Anacon, PDH and infomedia conferences.

drdlsharma@gmail.com

Tanshinone IIA could inhibit human hepatocellular carcinoma Hep-G2 cells through inducing ER stress in vitro

Chin-Cheng Su

Changhua Christian Hospital, Taiwan

Tanshinone IIA (Tan-IIA) is one of the diterpene quinone in *Salviae miltiorrhizae Radix*. Tan-IIA could inhibit many human cancer cells in vitro and in vivo through different molecular mechanisms. But the molecular mechanisms for Tan-IIA to inhibit hepatocellular carcinoma (H.C.C) were not well evaluated. In the present study, the cytotoxicity of Tan-IIA in H.C.C Hep-G2 cells was measured by M.T.T assay. The ER stress related protein expressions were evaluated by western blotter. For in vivo study, the Hep-G2 cells were implanted directly into SCID mice and then mice with Hep-G2 cells xenograft tumours were treated with Tan-IIA (I.P) every other day for 4 weeks. These mice were sacrificed with CO₂ inhalation. The xenograft tumours were dissected and extracted the total protein for western blot. These results showed that Tan-IIA could inhibit H.C.C Hep-G2 cells with time and dose dependent in vitro. Tan-IIA could inhibit the growth of Hep-G2 cells xenograft tumor when compared with the control group. The ER stress related protein expressions ATF6, Caspase 12 and CHOP were up regulated when compared with the control group. These finding indicate that Tan-IIA could inhibit Hep-G2 through inducing ER stress in vitro.

Biography

Chin Cheng Su has completed his Ph.D at the age of 42 years from Graduate Institute of Chinese Medical Science (2003-2006) from China Medical University, Taiwan. He is the director of tumor research center of integrative medicine and Co-Chair of the Comprehensive Breast cancer center and the Department of Surgery, Changhua Christian Hospital. He has published more than 36 papers in reputed journals and serving as a reviewer of reputed journals.

succ.maeva@msa.hinet.net